A shocking setback for the horse racing world: Zarak, the rising star of the breeding scene, will be absent from the upcoming season's start due to a stable accident. This news, announced by the Aga Khan Studs, has sent ripples through the industry.
Zarak, a descendant of champions, is the son of Dubawi and the Aga Khan's undefeated Zarkava. He was poised to continue his dominance in the 2026 covering season, with a fee of €80,000, building on his already impressive record.
But fate had other plans. The stud's statement reveals, "Zarak... will miss the start of the season... He will need weeks to recover, and his health will be re-evaluated in two months." This news is a significant blow, especially considering his remarkable journey since retiring to Haras de Bonneval in 2018.
His breeding prowess is evident with 22 individual group or graded winners, including Metropolitan, Haya Zark, and Zagrey. Zarak's success rate is remarkable, with a 10.7% strike rate of stakes winners-to-runners and an impressive 72% winners-to-runners ratio. And this is where it gets intriguing—his influence extends across the Atlantic.
In the U.S., Zarak's progeny have made their mark. Laurelin, Parnac, Village Voice, and Flatten the Curve are just a few of his offspring that have achieved notable victories in prestigious races. These successes have solidified Zarak's reputation as a sire of international caliber.
This unfortunate accident raises questions about the fragility of breeding plans and the impact on the industry. Will Zarak's absence create a void in the market? And what does this mean for the future of his lineage? The racing world awaits his recovery, eager to see if he can continue his remarkable breeding career.
What are your thoughts on this unexpected turn of events? Do you think Zarak's absence will significantly affect the breeding season, or will other sires step up to fill the void?
For more updates on the European racing scene, head to RacingPost.com, where you can stay informed about the latest developments in racing, sales, and bloodstock news.
